articleJournal of Bone and Mineral ResearchJan 1, 2003Closed access

The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

Oregon Health & Science University · Portland VA Medical Center · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Teriparatide [rhPTH(1-34)] increases bone mineral density and reduces the risk of vertebral fracture in women. We randomized 437 men with spine or hip bone mineral density more than 2 SD below the young adult male mean to daily injections of placebo, teriparatide 20 microg, or teriparatide 40 microg. All subjects also received supplemental calcium and vitamin D. The study was stopped after a median duration of 11 months because of a finding of osteosarcomas in rats in routine toxicology studies. Biochemical markers of bone formation increased early in the course of therapy and were followed by increases in indices of osteoclastic activity. Spine bone mineral density was greater than in placebo subjects after 3…

Citation impact

770
total citations
FWCI
40.58
Percentile
100%
References
28
Citations per year

Authors

9

Topics & keywords

Keywords
  • Teriparatide
  • Bone mineral
  • Medicine
  • Femoral neck
  • Osteoporosis
  • Internal medicine
  • Bone density
  • Placebo
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding